Summary
Highlights
Peptides are gaining attention beyond their traditional roles in fat loss and metabolic health, with emerging evidence suggesting their potential in reversing osteoarthritis in humans. The video highlights three key factors peptides can combat: pain, inflammation, and destruction.
Preclinical studies using liraglutide, a peptide in the same class as the main one discussed, demonstrate its effectiveness in reducing pain in osteoarthritic animals. Higher doses of liraglutide lead to a greater threshold before pain is experienced, indicating its pain-relieving capabilities.
Peptides directly impact chondrocytes, cells in the joints responsible for structural proteins and inflammatory signaling. In osteoarthritis, inflammation leads to immune cell invasion and destruction. Studies show liraglutide significantly reduces inflammatory molecules like prostaglandin E (PGE) produced by chondrocytes, effectively halving PGE levels.
Liraglutide also dampens joint destruction by reducing the release of glycosaminoglycans, which are structural molecules in cartilage. Images of cartilage show preservation and possible renewal in the presence of the peptide, confirmed by averaged data indicating increased cartilage with peptide treatment.
A small clinical trial investigated semaglutide, a peptide similar to liraglutide, in humans. Patients receiving semaglutide alongside hyaluronic acid injections showed greater improvement in WOMAC scores (a measure of pain and function) compared to hyaluronic acid alone. Importantly, it led to an increase in cartilage thickness, indicating rejuvenation.
While promising, the study has critiques, including unblinded assessments of cartilage and inadequate controls to definitively state the effects are independent of weight loss. However, long-term associative studies corroborate these findings, suggesting semaglutide and similar peptides offer osteoarthritis benefits, potentially independent of weight loss, especially for metabolically-driven osteoarthritis.